Shortly after the discovery of TOP1 SUMOylation, it was demonstrated that exposure of mammalian cells to teniposide, a TOP2-targeting anti-cancer drug, resulted in SUMO-1 modification of both TOP2α and TOP2β (Mao et al., 2000a). This evidence concerns the gene TOP2A and cancer.